ROSSELL-TECHSYS
Rossell Techsys has been awarded a contract with Lockheed Martin to build Electrical Wire Harness and Interconnect System (EWIS) parts in support of Lockheed Martin’s MH-60R aircraft that are being supplied to the Indian Navy. Last year, India signed a USD $2.1 billion deal with the United States Government as part of its Foreign Military Sales program for the purchase of 24 Lockheed Martin anti-submarine MH-60R helicopters. The first three of these MH-60R all-weather helicopters, which can support multiple missions with state-of-the-art avionics and sensors, have been delivered to the Indian Navy and are currently undergoing pilot and crew training in the United States. The delivery of 24 helicopters will be completed in five years from the time the deal was concluded. The helicopters will be modified with a variety of "India-unique" equipment and weapons. The induction of these fourth-generation MH-60Rs is expected to further enhance the Indian Navy's three-dimensional capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110006132/en/
“We are honoured to have been selected to manufacture wire harnesses for the MH-60R, an important equipment for India. We are committed to producing high-quality parts, on time, from India, furthering India’s growing strength in manufacturing to global standards and contributing to Aatmanirbhar Bharat ,” said Mr. Prabhat Kumar Bhagvandas, Chief Executive Officer, Rossell Techsys.
As part of the contract received from Lockheed Martin, Rossell Techsys shall perform “Build to Print” (BTP) manufacture of the wire harnesses that will be installed on the MH-60R. Manufacture of these parts is being performed in the “Center of Excellence” (COE), set up by Rossell Techsys for Lockheed Martin platforms. The manufacture of parts has commenced, with the first parts having successfully undergone acceptance by Lockheed Martin. The contract shall also enable Lockheed Martin to obtain offset credits towards this platform sale.
“We are excited about the opportunity to partner with Rossell Techsys and confident of their vital capability to deliver high quality cable and harness assemblies in support of the India MRH Program and the Indian Navy,” said Hamid Salim, Vice President and General Manager, Sikorsky Maritime and Mission Systems.
About Lockheed Martin
Headquartered in Bethesda, Maryland, Lockheed Martin Corporation is a global security and aerospace company that employs approximately 114,000 people worldwide and is principally engaged in the research, design, development, manufacture, integration and sustainment of advanced technology systems, products and services.
Present in India for over three decades, Lockheed Martin is proud of its longstanding relationships and commitment to customers and partners on existing and future programs ranging from transport, maritime and fighter aircraft, to sea and land-based air and missile defence projects, as well as capabilities in civil sectors including new and renewable energy. A strategic partner and developer of sovereign industrial, workforce and enterprise capability, Lockheed Martin India’s joint ventures, apprenticeships, and founding membership of the India Innovation Growth Program underscore its conviction in Indian industry, talent and progress.
Please follow @LMNews on Twitter for the latest announcements and news across the company.
About Rossell Techsys
Rossell Techsys is the Aerospace & Defense Division of Rossell India Limited, a public listed company. It is an MSME, certified to AS9100, ISO 9001, ISO 14001, ISO 45001, ISO 27001, ISO 37001 and is also ISO 31000 and NIST 800-171 compliant. It operates from a state-of-the-art 225,000 sq. ft., LEED Gold rated facility at Bangalore, providing custom engineering and manufacturing services. Core competencies are in Electrical Wiring and Interconnect Systems (EWIS), Electronic System and Systems Integration (ESSI), Test Equipment and After Market Product Support Services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110006132/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom